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We aimed to replicate reported associations of 10 SNPs at eight distinct loci with overall ischemic 
stroke (IS) and its subtypes in an independent cohort of Dutch IS patients. We included 1,375 IS patients 
enrolled in a prospective multicenter hospital-based cohort in the Netherlands, and 1,533 population-
level controls of Dutch descent. We tested these SNPs for association with overall IS and its subtypes 
(large artery atherosclerosis, small vessel disease and cardioembolic stroke (CE), as classified by TOAST) 
using an additive multivariable logistic regression model, adjusting for age and sex. We obtained odds 
ratios (OR) with 95% confidence intervals (95% CI) for the risk allele of each SNP analyzed and exact 
p-values by permutation. We confirmed the association at 4q25 (PITX2) (OR 1.43; 95% CI, 1.13–1.81, 
p = 0.029) and 16q22 (ZFHX3) (OR 1.62; 95% CI, 1.26–2.07, p = 0.001) as risk loci for CE. Locus 16q22 
was also associated with overall IS (OR 1.24; 95% CI, 1.08–1.42, p = 0.016). Other loci previously 
associated with IS and/or its subtypes were not confirmed. In conclusion, we validated two loci (4q25, 
16q22) associated with CE. In addition, our study may suggest that the association of locus 16q22 may 
not be limited to CE, but also includes overall IS.
A substantial proportion of the etiology of acute ischemic stroke (IS) is thought to be attributable to (common) 
genetic variation1. Genome-wide association studies (GWAS) have estimated that the proportion of phenotypic 
variance of IS explained by common variants ranges between 16 and 40%, depending on subtype1. Thus far, 
GWAS have identified a small number of single nucleotide polymorphisms (SNPs) associated with overall IS or its 
subtypes large artery atherosclerosis (LAA), small vessel disease (SVD) and cardioembolism (CE)2–11. These loci 
have been suggested to be mostly or entirely subtype specific. Discovery of common variants influencing stroke 
is hindered by many challenges, including but not limited to the heterogeneity of the phenotype, high lifetime 
risk of stroke, late disease onset, and limited statistical power in studies performed to date. Thus, replication of 
presumed risk loci in independent cohorts is emphatically recommended before initiating fine-mapping efforts 
in search of causal variants and functional studies to discern the functional consequences of these variants12. We 
aimed to replicate the associations of eight loci with IS and/or its subtypes as previously reported in an independ-
ent set of patients with IS drawn from a Dutch cohort.
Methods
Participants. We included 1,375 patients with IS of Dutch descent who were enrolled in the Dutch Parelsnoer 
initiative (PSI) Cerebrovascular Disease13. This study represents an ongoing collaboration of eight university 
medical centers in the Netherlands in which clinical data, imaging and biomaterials of patients with stroke are 
prospectively and uniformly collected13. The present study includes patients with IS enrolled between September 
2009 and November 2014. IS was defined as focal neurologic deficits of sudden onset originating from the brain 
and persisting for more than 24 hours, in the absence of hemorrhage as confirmed by imaging. We further 
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classified IS subtypes according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST), LAA, SVD, CE, 
and stroke of other and of undetermined cause14. We used 1,533 population-level controls of Dutch descent15. 
Information on ancestry in patients and controls was obtained by self-report. The Medical Ethics Committee of 
the University Medical Center Utrecht approved the study and all patients provided written informed consent. 
The research described was conducted in accordance with relevant guidelines and regulations.
Genotyping. DNA of the cases and controls was extracted from peripheral blood. We genotyped 10 SNPs of 
eight loci (1p13.2 (TSPAN2), 4q25 (PITX2), 6p21.1 (SUPT3H/CDC5L), 7p21.1 (HDAC9), 9p21.3 (CDKN2BAS1), 
9q34 (ABO), 12q24 (ALDH2) and 16q22 (ZFHX3)) using KASP assays (LGC Genomics, Hoddesdon, UK).
Statistical analysis. We removed individuals with >25% missing genotypes (29 individuals; 7 cases and 22 
controls). We tested each SNP for deviation from Hardy-Weinberg equilibrium (p < 0.001) and calculated minor 
allele frequencies for each SNP in cases and controls. As the design of the study prevented us from performing 
principal component analyses to test for ancestral homogeneity, we compared risk allele frequencies with those 
from the Genome of the Netherlands (GoNL) Project16. GoNL comprises a comprehensive characterization of 
genetic variation of 769 individuals of Dutch ancestry as assessed by whole-genome sequencing16. Frequencies 
were calculated in the unrelated set of individuals in GoNL (N = 498). Next, we tested these SNPs for association 
with IS and its subtypes using an additive logistic regression model, which includes 0, 1 or 2 copies of the risk 
alleles, and adjusted for age and sex. We report odds ratios (OR) with 95% confidence intervals (95% CI) for 
each risk allele as established in previous studies2,4. To assess the validity of also including samples with missing 
genotypes, we performed a sensitivity analysis excluding each individual with at least one missing genotype. 
Accompanying exact probability-values for the observed associations were obtained by performing 10,000 per-
mutations. Analyses were performed in Plink version 1.9b3.38.
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Results
After quality control, our data set consisted of 1,368 IS patients (803 (58.7%) men, median age 67.3 years (inter-
quartile range (IQR): 56.5–77.2)) and 1,511 controls of Dutch descent (926 (61.3%) men, median age 64.4 years 
(IQR: 58.0–70.3)). Baseline characteristics of the patients with IS are presented in Supplementary Table S1 online. 
All genotyped SNPs had call rates >98% and were in Hardy-Weinberg equilibrium. Risk allele frequency of all 
variants showed high concordance with those reported in the Genome of the Netherlands Project (Table 1)16.
At the 4q25 (PITX2) locus, previously identified by GWAS, we confirmed the association at rs2634074 with CE 
stroke (OR = 1.43 for the T allele; 95% CI, 1.13–1.81, p = 0.029), but not at rs2200733 (OR = 1.30 for the T allele; 
95% CI, 0.96–1.76; p = 0.60) (Table 1). We also replicated 16q22 (ZFHX3) as a risk locus for CE (OR = 1.62 for the 
T allele; 95% CI, 1.26–2.07, p = 0.0014) and found this locus significantly associated with overall IS (OR = 1.28 for 
the T allele; 95% CI, 1.12–1.47, p = 0.002) (Table 1). This association remained significant in a sensitivity analysis 
excluding cases with cardioembolic stroke (OR = 1.18; 95% CI, 1.03–1.36, p = 0.02), and when we only included 
patients with LAA stroke or SVD (OR = 1.22; 95% CI, 1.03–1.45, p = 0.02).
We could not replicate the previously-established associations at the 1p13.2 (TSPAN2), 6p21.1 (SUPT3H/
CDC5L), 7p21.1 (HDAC9), 9p21.3 (CDKN2B-AS1), 9q34 (ABO) and 12q24 (ALDH2) loci with overall IS or its 
subtypes. However, all of the effect directions were consistent with the observed directions of the initial associa-
tion reports except for the C allele of rs556621 at locus 6p21.1 (SUPT3H/CDC5L) (Table 1).
Results did essentially not differ when individuals with missing genotypes were excluded (Supplementary 
Table S2).
Discussion
In a well-defined cohort of patients with IS, we confirmed the 4q25 (PITX2) and 16q22 (ZFHX3) loci to be signif-
icantly associated with the IS subtype CE. We also found locus 16q22 to be significantly associated with overall IS. 
We were not able to replicate the previously-established associations at the 1p13.2 (TSPAN2), 6p21.1 (SUPT3H/
CDC5L), 7p21.1 (HDAC9), 9p21.3 (CDKN2B-AS1), 9q34 (ABO) and 12q24 (ALDH2) with overall IS or its sub-
types although, barring locus 6p21.1 (SUPT3H/CDC5L), the effect direction of their associations were consistent 
with expectation2–11.
Previous studies have consistently demonstrated the association between variants at 4q25 (PITX2) and 16q22 
(ZFHX3) with atrial fibrillation both in patients with and without IS3,10, and additionally with cardioembolic 
stroke2–4. In the 4q25 locus, we only replicated rs2634074, but not rs2200733, despite moderate linkage disequi-
librium (r2 = 0.51) and a comparable effect size as established previously2–4,9. This finding is likely explained by 
the difference in the power to detect a statistically-significant signal at each SNP (95% and 56%, respectively), a 
difference that results from their ~10% frequency difference. After the initial report of the association10, other 
studies found locus 16q22 to be specific for CE2,4, whereas our findings point to a possible association with both 
CE and overall IS. The association with overall IS remained significant after excluding cases with cardioembolic 
stroke, possibly suggesting a partially shared genetic architecture across different stroke subtypes17.
Variants near PITX2 that encode for a transcription factor have convincingly been implicated in sinoatrial 
node development and regulation of cardiac action potentials18. Little is known about the role of ZFHX3 in 
ischemic stroke. Besides atrial fibrillation, this gene has also been implicated in the regulation of myogenic and 
neuronal differentiation, and as a tumor suppressor gene in multiple cancers. Additionally, sequence variants in 
the locus have been linked to Kawasaki disease10. These lines of evidence may suggest that the role of this locus 
in IS might not be restricted to those of cardiac origin, and therefore may explain its potential association with 
overall IS.
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While recent publications have suggested that implicated variants are likely subtype specific2,4, it is noteworthy 
that some genetic overlap between diagnostic IS subtypes has also been reported17. Given the repeated discovery 
of this locus in cardioembolic stroke in large-scale GWAS, it is likely that the observed association of locus 16q22 
with overall IS in this study is driven by a subset of patients with another IS subtype that may also have as yet 
undiscovered atrial fibrillation or cardioembolic stroke. In addition, significant associations of genetic risk scores 
for atrial fibrillation with overall IS were recently found to be almost entirely explained by an association with 
cardioembolic stroke19.
Several factors may have prevented us from being able to replicate all associations investigated here. First, we 
had limited power to discover (nominal) associations in a relatively limited cohort size; our power was particu-
larly limited for lower-frequency variants or variants with modest effect, a characteristic true of the vast majority 
of loci discovered through genome-wide association studies (stroke loci included). Thus, it is entirely possible 
that non-replicated loci are truly associated with overall IS and its subtypes and would replicate in larger sample 
collections. Second, failure to replicate may also be due to phenotypic heterogeneity; subtyping approaches vary 
across studies, and subtyping is imperfect, as many samples are categorized as ‘undetermined,’ thus allowing 
for potentially incorrectly subtyped cases (and consequently, reducing power). However, to decrease diagnostic 
uncertainty we excluded patients with transient ischemic attacks. Despite these limitations, most variants showed 
comparable effect sizes in the same direction as reported previously.
In conclusion, we validated two loci (4q25, 16q22) associated with IS caused by CE. In addition, our study may 
suggest that locus 16q22 may also be associated with overall IS or another subtype for which the current study 
may lack power to demonstrate a significant association. Future studies should search for the causal variants 
underlying these loci by fine-mapping and further discerning which genes within the loci may have functional 
consequence for disease.
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www.nature.com/scientificreports/
4Scientific RepoRts | 7: 12175  | DOI:10.1038/s41598-017-07404-4
 11. Bellenguez, C. et al. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. Nat. 
Genet. 44, 328–33 (2012).
 12. Manolio, T. A. Bringing genome-wide association findings into clinical use. Nat. Rev. Genet. 14, 549–58 (2013).
 13. Nederkoorn, P. J. et al. The Dutch String-of-Pearls Stroke Study: Protocol of a large prospective multicenter genetic cohort study. Int. 
J. Stroke 10, 120–122 (2015).
 14. Adams, H. et al. (TOAST) Classification of Subtype of Acute Ischemic Stroke. Stroke 23, 35–41 (1993).
 15. Huisman, M. H. B. et al. Family history of neurodegenerative and vascular diseases in ALS: A population-based study. Neurology 77, 
1363–1369 (2011).
 16. Genome of the Netherlands Consortium. Whole-genome sequence variation, population structure and demographic history of the 
Dutch population. Nat. Genet. 46, 818–25 (2014).
 17. Holliday, E. G. et al. Genetic overlap between diagnostic subtypes of ischemic stroke. Stroke 46, 615–619 (2015).
 18. Kirchhof, P. et al. PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility 
and complex changes in gene expression. Circ. Cardiovasc. Genet. 4, 123–133 (2011).
 19.  Lubitz, S. A. et al. Atrial fibrillation genetic risk and ischemic stroke mechanisms. Stroke., doi:10.1161/STROKEAHA.116.016198 
(2017).
Acknowledgements
This study was funded by Parelsnoer Institute (PSI), which was co-financed by the Dutch Government, the Dutch 
Federation of University Medical Centers (UMC) and the eight UMCs (from 2007–2011). The continuation of 
the PSI is financed by the UMCs. Y.M. Ruigrok was supported by a clinical fellowship grant of the Netherlands 
Organization for Scientific Research (NWO) (project no. 40-00703-98-13533). C.J.M. Klijn is supported by a 
clinical established investigator grant from the Dutch Heart Foundation (2012T077), and an ASPASIA grant 
from The Netherlands Organisation for Health Research and Development, ZonMw (grant number 015008048).
Author Contributions
P.I.W.B., J.H.V., Y.M.R., contributed to the study concept and design. L.H.B., E.J.D., P.J.K., G.J.L., P.J.N., R.J.O., 
M.C.V., M.J.W., L.J.K., J.H.V., Y.M.R. participated in data collection. A.J.H., S.L.P., C.J.M.K., A.A., P.I.W.B., J.H.V., 
Y.M.R. contributed to the analysis and interpretation of data. A.H. wrote the manuscript. S.L.P., C.J.M.K., A.A., 
L.J.K., P.I.W.B., J.H.V., Y.M.R. revised the manuscript for important intellectual content. C.J.M.K., P.I.W.B., J.H.V., 
Y.M.R. provided study supervision and obtained funding. The data presented in this article were obtained from 
the Dutch Parelsnoer Institute-Cerebrovascular accident (CVA) Study. As such, the investigators within this 
consortium all contributed to the collection of data.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-07404-4
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
www.nature.com/scientificreports/
5Scientific RepoRts | 7: 12175  | DOI:10.1038/s41598-017-07404-4
Consortia
Dutch Parelsnoer Institute-Cerebrovascular accident (CVA) Study Group
Catharina J.M. Klijn1,4,5, Ale Algra1,3,4,6, Ewoud J. van Dijk4,5, Peter J. Koudstaal4,7, 
 Gert-Jan Luijckx4,8, Paul J. Nederkoorn4,9, Robert J. van Oostenbrugge4,10, Marieke C. 
Visser4,11, Marieke J. Wermer4,12 & L. Jaap Kappelle1,4
5Department of Neurology, Donders Institute of Brain Behaviour & Cognition, Center for Neuroscience, Radboud 
University Medical Center, Nijmegen, The Netherlands. 6Department of Clinical Epidemiology, Leiden University 
Medical Center, Leiden, The Netherlands. 7Department of Neurology, Erasmus Medical Center, Rotterdam, 
The Netherlands. 8Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands. 
9Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands. 10Department of Neurology, 
Maastricht University Medical Center, Maastricht, The Netherlands. 11Department of Neurology, VU Medical 
Center, Amsterdam, The Netherlands. 12Department of Neurology, Leiden University Medical Center, Leiden, 
The Netherlands. 
